Skip to main content
SpringerLink
Log in

Research Pipeline II: Upcoming Biologic Therapies

  • Chapter
  • First Online:
Advances in Psoriasis

  • 667 Accesses

Abstract

Psoriasis is a chronic inflammatory condition mediated by activated T-cells. Cutaneous manifestations of psoriasis have been shown to have a tremendous impact on quality of life, particularly in patients with moderate to severe disease. Given the high morbidity associated with psoriasis, disease control is paramount. Systemic treatments are indicated for effective management of cutaneous disease and the comorbidities that result from chronic inflammation. Prior systemic treatments were non-specific and associated with significant side effect profiles. With the development of biologics, treatments have become increasingly targeted and efficacious. This chapter will review biologic drugs currently in development that may eventually add to the growing armamentarium of psoriasis treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

    Article  Google Scholar 

  2. Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.

    Article  Google Scholar 

  3. Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–9.

    PubMed  PubMed Central  Google Scholar 

  4. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.

    Article  Google Scholar 

  5. Georgescu SR, Tampa M, Caruntu C, Sarbu MI, Mitran CI, Mitran MI, et al. Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 2019;20(3):739.

    Article  CAS  Google Scholar 

  6. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.

    Article  CAS  Google Scholar 

  7. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005(5):273–9.

    Article  Google Scholar 

  8. Hamilton JA. GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015;11(4):457–65.

    Article  CAS  Google Scholar 

  9. De Bock M, Hulstaert E, Kruse V, Brochez L. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review. Case Rep Dermatol. 2018;10(2):190–7.

    Article  Google Scholar 

  10. Shin D, Kim DS, Kim SH, Je JH, Kim HJ, Young Kim D, et al. Decreased PD-1 positive blood follicular helper T cells in patients with psoriasis. Arch Dermatol Res. 2016;308(8):593–9.

    Article  CAS  Google Scholar 

  11. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.

    Article  CAS  Google Scholar 

  12. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(2):AB8.

    Google Scholar 

  13. Junod SW. FDA and clinical drug trials: a short history FDA. Available from https://www.fda.gov/media/110437/download.

  14. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.

    Article  CAS  Google Scholar 

  15. Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.

    Article  CAS  Google Scholar 

  16. Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32.

    Article  CAS  Google Scholar 

  17. Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–86.e10.

    Article  CAS  Google Scholar 

  18. Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, et al. AB0738 dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, phase 2B extension study. Ann Rheum Dis. 2019;78(Suppl 2):1834.

    Google Scholar 

  19. Available from: https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-Positive-Results-Confirmed-in-Second-Phase-3-Psoriasis-Study.

  20. BIOCAD registered the first Russian original therapeutic monoclonal antibody 2020. Available from: https://biocadglobal.com/post/Russian_original_therapeutic_monoclonal_antibody.

  21. Bakulev AS, Kubanov AA, Khairutdinov V, Kokhan M, Artemyeva A, Derbin S, Chernyaeva E, Ivanov R. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. Vestn Dermatol Venerol. 2019;95(3):54–64.

    Article  Google Scholar 

  22. Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019;81(1):196–203.

    Article  CAS  Google Scholar 

  23. 2019 [cited 2020]. Available from: https://www.affibody.se/affibody-announces-interim-analysis-in-phase-2-psoriasis-trial-of-aby-035/.

  24. Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88–95.

    Article  CAS  Google Scholar 

  25. https://www.globenewswire.com/news-release/2020/05/06/2028827/0/en/AnaptysBio-Announces-First-Quarter-2020-Financial-Results-and-Provides-Pipeline-Updates.html

  26. Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2019;180(6):1352–60.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Ahuva D. Cices & Jeffrey M. Weinberg

Authors
  1. Ahuva D. Cices
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey M. Weinberg .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cices, A.D., Weinberg, J.M. (2021). Research Pipeline II: Upcoming Biologic Therapies. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation